European Pharmaceutical Market Access, Pricing & Reimbursement
SMi Group’s 22nd annual European Pharmaceutical Market Access, Pricing and Reimbursement conference returns to London from 10-11 October 2016. The conference is one of the most established in the world, focusing on the changes in pricing and reimbursement and market access.
As pharmaceutical global spending is predicted to increase by 29-32% by 2020*, the need for access to cheaper alternative medicines and technology is essential. The use of generics is on the rise and it's expected that by 2020, 88%* of total medicine use will be attributed to generics, over the counter, and non-original branded products.
This year's agenda will have a strong focus on the future of pricing and reimbursement. Other key topics include:
Updates on AMNOG and its implication on pricing and reimbursement How biosimilars are affecting your pricing strategy Capture on emerging markets’ regulatory framework to adapt your market access and P&R models Orphan drugs using recent examples to highlight the impact on pricing Cancer drug funding and budget cuts in the UK Innovative solutions beyond the pill Japanese and Turkish regional updates
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Global site License Fulfilled By Publisher